{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:51:09Z","timestamp":1789696269357,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T00:00:00Z","timestamp":1447027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1208\/s12249-015-0439-1","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T20:42:54Z","timestamp":1447101774000},"page":"1110-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica"],"prefix":"10.1208","volume":"17","author":[{"given":"Maryam Heidari","family":"Kharaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delaram","family":"Doroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"issue":"6","key":"439_CR1","doi-asserted-by":"crossref","first-page":"e2313","DOI":"10.1371\/journal.pone.0002313","volume":"3","author":"FM Dossin","year":"2008","unstructured":"Dossin FM, Dufour A, Dusch E, Siqueira-Neto JL, Moraes CB, Yang GS, et al. Automated nuclear analysis of Leishmania major telomeric clusters reveals changes in their organization during the parasite\u2019s life cycle. PloS one. 2008;3(6):e2313.","journal-title":"PloS one"},{"issue":"10","key":"439_CR2","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1371\/journal.pntd.0000285","volume":"2","author":"R Reithinger","year":"2008","unstructured":"Reithinger R. Leishmaniases\u2019 burden of disease: ways forward for getting from speculation to reality. PLoS Negl Trop Dis. 2008;2(10):e285.","journal-title":"PLoS Negl Trop Dis"},{"key":"439_CR3","doi-asserted-by":"crossref","unstructured":"Trufant JW, Lewin JM, Hale CS, Meehan SA, Pomeranz MK. New world cutaneous leishmaniasis. Dermatol Online J. 2015;20(12).","DOI":"10.5070\/D32012025051"},{"issue":"2","key":"439_CR4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/08982104.2012.762519","volume":"23","author":"A Momeni","year":"2013","unstructured":"Momeni A, Rasoolian M, Momeni A, Navaei A, Emami S, Shaker Z, et al. Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis. J Liposome Res. 2013;23(2):134\u201344.","journal-title":"J Liposome Res"},{"issue":"5","key":"439_CR5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00436-007-0638-0","volume":"101","author":"R Hadighi","year":"2007","unstructured":"Hadighi R, Boucher P, Khamesipour A, Meamar A, Roy G, Ouellette M, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res. 2007;101(5):1319\u201322.","journal-title":"Parasitol Res"},{"issue":"4","key":"439_CR6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00436-012-2996-5","volume":"111","author":"BS Raju","year":"2012","unstructured":"Raju BS, Gurumurthy S, Kuhls K, Bhandari V, Schnonian G, Salotra P. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India. Parasitol Res. 2012;111(4):1559\u201368.","journal-title":"Parasitol Res"},{"key":"439_CR7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","volume":"61","author":"J Alvar","year":"2006","unstructured":"Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol. 2006;61:223\u201374.","journal-title":"Adv Parasitol"},{"issue":"4","key":"439_CR8","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1128\/AAC.00524-10","volume":"55","author":"A Banerjee","year":"2011","unstructured":"Banerjee A, De M, Ali N. Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrob Agents Chemother. 2011;55(4):1661\u201370.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"439_CR9","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01319-08","volume":"53","author":"MR Jaafari","year":"2009","unstructured":"Jaafari MR, Bavarsad N, Bazzaz BSF, Samiei A, Soroush D, Ghorbani S, et al. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB\/c mice. Antimicrob Agents Chemother. 2009;53(6):2259\u201365.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"439_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/dta.339","volume":"5","author":"W Khan","year":"2013","unstructured":"Khan W, Sharma SS, Kumar N. Bioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheres. Drug Test Anal. 2013;5(6):453\u201360.","journal-title":"Drug Test Anal"},{"issue":"2","key":"439_CR11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","volume":"164","author":"A Jhingran","year":"2009","unstructured":"Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R. Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol. 2009;164(2):111\u20137.","journal-title":"Mol Biochem Parasitol"},{"issue":"1","key":"439_CR12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08982100903015025","volume":"20","author":"G Carneiro","year":"2010","unstructured":"Carneiro G, Santos DC, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA, et al. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res. 2010;20(1):16\u201323.","journal-title":"J Liposome Res"},{"issue":"8","key":"439_CR13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","volume":"25","author":"M Solomon","year":"2011","unstructured":"Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol. 2011;25(8):973\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"439_CR14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1081\/DDC-120030423","volume":"30","author":"LS Ferreira","year":"2004","unstructured":"Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm. 2004;30(3):289\u201396.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"439_CR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1051\/parasite\/1997042133","volume":"4","author":"T Fusai","year":"1997","unstructured":"Fusai T et al. Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major\/mouse model. Parasite. 1997;4(2):133\u20139.","journal-title":"Parasite"},{"issue":"4","key":"439_CR16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1381612023396258","volume":"8","author":"SL Croft","year":"2002","unstructured":"Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des. 2002;8(4):319\u201342.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"439_CR17","first-page":"85","volume":"15","author":"B Shazad","year":"2005","unstructured":"Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice\/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol. 2005;15(2):85\u20137.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"439_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.actatropica.2004.03.009","volume":"91","author":"RX Armijos","year":"2004","unstructured":"Armijos RX, Weigel MM, Calvopi\u00f1a M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 2004;91(2):153\u201360.","journal-title":"Acta Trop"},{"issue":"1","key":"439_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0168-3659(94)90047-7","volume":"30","author":"C Schwarz","year":"1994","unstructured":"Schwarz C, Mehnert W, Lucks J, M\u00fcller R. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release. 1994;30(1):83\u201396.","journal-title":"J Control Release"},{"issue":"1","key":"439_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"RH Mu\u00c8ller","year":"2000","unstructured":"Mu\u00c8ller RH, Ma\u00c8der K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161\u201377.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"439_CR21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.addr.2007.04.009","volume":"59","author":"AA Date","year":"2007","unstructured":"Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):505\u201321.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"439_CR22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1208\/pt0804083","volume":"8","author":"K Vivek","year":"2007","unstructured":"Vivek K, Reddy H, Murthy RS. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2007;8(4):16\u201324.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"439_CR23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1358\/mf.2005.27.2.876286","volume":"27","author":"K Manjunath","year":"2005","unstructured":"Manjunath K, Reddy J, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol. 2005;27(2):127\u201344.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"6","key":"439_CR24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1208\/s12249-014-0168-x","volume":"15","author":"MN Patel","year":"2014","unstructured":"Patel MN, Lakkadwala S, Majrad MS, Injeti ER, Gollmer SM, Shah ZA, et al. Characterization and evaluation of 5-fluorouracil-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification technique. AAPS PharmSciTech. 2014;15(6):1498\u2013508.","journal-title":"AAPS PharmSciTech"},{"key":"439_CR25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.colsurfb.2011.11.051","volume":"93","author":"DM Ridolfi","year":"2012","unstructured":"Ridolfi DM, Marcato PD, Justo GZ, Cordi L, Machado D, Dur\u00e1n N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf B: Biointerfaces. 2012;93:36\u201340.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"1","key":"439_CR26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1208\/s12249-009-9197-2","volume":"10","author":"G Abdelbary","year":"2009","unstructured":"Abdelbary G, Fahmy RH. Diazepam-loaded solid lipid nanoparticles: design and characterization. Aaps Pharmscitech. 2009;10(1):211\u20139.","journal-title":"Aaps Pharmscitech"},{"issue":"1","key":"439_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-11-72","volume":"11","author":"R Nair","year":"2012","unstructured":"Nair R, Kumar AC, Priya VK, Yadav CM, Raju PY. Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine. Lipids Health Dis. 2012;11(1):1\u20138.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"439_CR28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3109\/03639045.2010.539231","volume":"37","author":"L Montenegro","year":"2011","unstructured":"Montenegro L, Campisi A, Sarpietro MG, Carbone C, Acquaviva R, Raciti G, et al. In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm. 2011;37(6):737\u201346.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"439_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/AAP.0b013e31823fc058","volume":"37","author":"F Leng","year":"2012","unstructured":"Leng F, Wan J, Liu W, Tao B, Chen X. Prolongation of epidural analgesia using solid lipid nanoparticles as drug carrier for lidocaine. Reg Anesth Pain Med. 2012;37(2):159\u201365.","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"439_CR30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2011.12.037","volume":"424","author":"M Ghadiri","year":"2012","unstructured":"Ghadiri M, Fatemi S, Vatanara A, Doroud D, Najafabadi AR, Darabi M, et al. Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. Int J Pharm. 2012;424(1):128\u201337.","journal-title":"Int J Pharm"},{"key":"439_CR31","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijantimicag.2010.06.023","volume":"36","author":"JAR Postigo","year":"2010","unstructured":"Postigo JAR. Leishmaniasis in the World Health Organization Eastern Mediterranean Region. Int J Antimicrob Agents. 2010;36:S62\u2013S5.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"439_CR32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12257-010-0331-5","volume":"16","author":"M Ghadiri","year":"2011","unstructured":"Ghadiri M, Vatanara A, Doroud D, Najafabadi AR. Paromomycin loaded solid lipid nanoparticles: characterization of production parameters. Biotechnol Bioprocess Eng. 2011;16(3):617\u201323.","journal-title":"Biotechnol Bioprocess Eng"},{"issue":"9","key":"439_CR33","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.00207-08","volume":"52","author":"AS Downey","year":"2008","unstructured":"Downey AS, Chong CR, Graczyk TK, Sullivan DJ. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrob Agents Chemother. 2008;52(9):3106\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"439_CR34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5173(01)00882-1","volume":"231","author":"N Sch\u00f6ler","year":"2002","unstructured":"Sch\u00f6ler N, Hahn H, M\u00fcller R, Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm. 2002;231(2):167\u201376.","journal-title":"Int J Pharm"},{"issue":"2","key":"439_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.parint.2005.01.001","volume":"54","author":"A Dutta","year":"2005","unstructured":"Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M. Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int. 2005;54(2):119\u201322.","journal-title":"Parasitol Int"},{"issue":"7","key":"439_CR36","first-page":"8","volume":"13","author":"A Khosravi","year":"2011","unstructured":"Khosravi A, Sharifi I, Barati M, Zarean M, Hakimi-Parizi M. Anti-leishmanial effect of nanosilver solutions on Leishmania tropica promastigotes by in-vitro assay. Zahedan J Res Med Sci. 2011;13(7):8\u201312.","journal-title":"Zahedan J Res Med Sci"},{"key":"439_CR37","doi-asserted-by":"crossref","unstructured":"Jain SK, Sahu R, Walker LA, Tekwani BL. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp: JoVE. 2012(70).","DOI":"10.3791\/4054"},{"key":"439_CR38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejps.2014.06.010","volume":"62","author":"J Schwartz","year":"2014","unstructured":"Schwartz J, Moreno E, Fern\u00e1ndez C, Navarro-Blasco I, Nguewa PA, Palop JA, et al. Topical treatment of L. major infected BALB\/c mice with a novel diselenide chitosan hydrogel formulation. Eur J Pharm Sci. 2014;62:309\u201316.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"439_CR39","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","volume":"19","author":"SL Croft","year":"2003","unstructured":"Croft SL, Coombs GH. Leishmaniasis\u2014current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19(11):502\u20138.","journal-title":"Trends Parasitol"},{"issue":"10","key":"439_CR40","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","volume":"17","author":"SL Croft","year":"2011","unstructured":"Croft SL, Olliaro P. Leishmaniasis chemotherapy\u2014challenges and opportunities. Clin Microbiol Infect. 2011;17(10):1478\u201383.","journal-title":"Clin Microbiol Infect"},{"issue":"25","key":"439_CR41","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","volume":"356","author":"S Sundar","year":"2007","unstructured":"Sundar S, Jha T, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356(25):2571\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"439_CR42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/0975-8453.59509","volume":"1","author":"P Shah","year":"2010","unstructured":"Shah P, Bhalodia D, Shelat P. Nanoemulsion: a pharmaceutical review. Sys Rev Pharm. 2010;1(1):24.","journal-title":"Sys Rev Pharm"},{"issue":"15","key":"439_CR43","first-page":"2713","volume":"26","author":"KY Win","year":"2005","unstructured":"Win KY, Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biogeosciences. 2005;26(15):2713\u201322.","journal-title":"Biogeosciences"},{"issue":"1","key":"439_CR44","first-page":"80","volume":"2","author":"P Ekambaram","year":"2012","unstructured":"Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Sci Rev Chem Commun. 2012;2(1):80\u2013102.","journal-title":"Sci Rev Chem Commun"},{"issue":"5","key":"439_CR45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/AAC.26.5.745","volume":"26","author":"J El-On","year":"1984","unstructured":"El-On J, Jacobs G, Witztum E, Greenblatt C. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother. 1984;26(5):745\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"439_CR46","first-page":"538","volume":"3","author":"T Garnier","year":"2002","unstructured":"Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs. 2002;3(4):538\u201344.","journal-title":"Curr Opin Investig Drugs"},{"issue":"4","key":"439_CR47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1023\/A:1012043315093","volume":"14","author":"RH M\u00fcller","year":"1997","unstructured":"M\u00fcller RH, R\u00fchl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14(4):458\u201362.","journal-title":"Pharm Res"},{"key":"439_CR48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0378-5173(96)04539-5","volume":"138","author":"RH M\u00fcller SM","year":"1996","unstructured":"M\u00fcller SM RH, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylactide\/glycolide particles and solid lipid nanoparticles. Int J Pharm. 1996;138:85\u201394.","journal-title":"Int J Pharm"},{"issue":"1","key":"439_CR49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijpharm.2006.12.045","volume":"337","author":"W Weyenberg","year":"2007","unstructured":"Weyenberg W, Filev P, Van den Plas D, Vandervoort J, De Smet K, Sollie P, et al. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm. 2007;337(1):291\u20138.","journal-title":"Int J Pharm"},{"issue":"2","key":"439_CR50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.toxlet.2009.03.014","volume":"188","author":"HL Karlsson","year":"2009","unstructured":"Karlsson HL, Gustafsson J, Cronholm P, M\u00f6ller L. Size-dependent toxicity of metal oxide particles\u2014a comparison between nano-and micrometer size. Toxicol Lett. 2009;188(2):112\u20138.","journal-title":"Toxicol Lett"},{"issue":"4","key":"439_CR51","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/nl052396o","volume":"6","author":"BD Chithrani","year":"2006","unstructured":"Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6(4):662\u20138.","journal-title":"Nano Lett"},{"issue":"1","key":"439_CR52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/smll.200700595","volume":"4","author":"N Lewinski","year":"2008","unstructured":"Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4(1):26\u201349.","journal-title":"Small"},{"issue":"2","key":"439_CR53","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/toxsci\/kfi256","volume":"88","author":"L Braydich-Stolle","year":"2005","unstructured":"Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann M-C. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci. 2005;88(2):412\u20139.","journal-title":"Toxicol Sci"},{"issue":"11","key":"439_CR54","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/smll.200700378","volume":"3","author":"Y Pan","year":"2007","unstructured":"Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size\u2010dependent cytotoxicity of gold nanoparticles. Small. 2007;3(11):1941\u20139.","journal-title":"Small"},{"issue":"3","key":"439_CR55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.taap.2006.10.004","volume":"217","author":"W Lin","year":"2006","unstructured":"Lin W, Huang Y-w, Zhou X-D, Ma Y. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 2006;217(3):252\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"43","key":"439_CR56","doi-asserted-by":"crossref","first-page":"13608","DOI":"10.1021\/jp712087m","volume":"112","author":"C Carlson","year":"2008","unstructured":"Carlson C, Hussain SM, Schrand AM, Braydich-Stolle KL, Hess KL, Jones RL, et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B. 2008;112(43):13608\u201319.","journal-title":"J Phys Chem B"},{"issue":"12","key":"439_CR57","first-page":"2137","volume":"28","author":"M-K Lee","year":"2007","unstructured":"Lee M-K, Lim S-J, Kim C-K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biogeosciences. 2007;28(12):2137\u201346.","journal-title":"Biogeosciences"},{"issue":"3","key":"439_CR58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nnano.2008.30","volume":"3","author":"W Jiang","year":"2008","unstructured":"Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nature Nanotechnol. 2008;3(3):145\u201350.","journal-title":"Nature Nanotechnol"},{"issue":"3","key":"439_CR59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0001-706X(92)90042-V","volume":"51","author":"A Gebre-Hiwot","year":"1992","unstructured":"Gebre-Hiwot A, Tadesse G, Croft S, Frommel D. An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop. 1992;51(3):237\u201345.","journal-title":"Acta Trop"},{"issue":"1","key":"439_CR60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/142.1.83","volume":"142","author":"JD Berman","year":"1980","unstructured":"Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis. 1980;142(1):83\u20136.","journal-title":"J Infect Dis"},{"issue":"2","key":"439_CR61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/infdis\/154.2.323","volume":"154","author":"DL Looker","year":"1986","unstructured":"Looker DL, Martinez S, Horton JM, Marr JJ. Growth of Leishmania donovani amastigotes in the continuous human macrophage cell line U937: studies of drug efficacy and metabolism. J Infect Dis. 1986;154(2):323\u20137.","journal-title":"J Infect Dis"},{"issue":"5","key":"439_CR62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/14.5.463","volume":"14","author":"R Neal","year":"1984","unstructured":"Neal R, Croft S. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother. 1984;14(5):463\u201375.","journal-title":"J Antimicrob Chemother"},{"key":"439_CR63","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2307\/3281406","volume":"70","author":"JD Berman","year":"1984","unstructured":"Berman JD. Leishmania tropica: quantitation of in vitro activity of antileishmanial agents by Giemsa staining, viability, and 3H-formycin B incorporation. J Parasitol. 1984;70:561\u20132.","journal-title":"J Parasitol"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-015-0439-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-015-0439-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-015-0439-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-015-0439-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T18:29:01Z","timestamp":1653503341000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-015-0439-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1208\/s12249-015-0439-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,9]]}}}